Table 1.
Prognostic relevance of tertiary lymphoid tissue in primary tumors.
| Type of cancer | TLT cellular composition | Prognostic marker | Methodology | Prognostic value | Number of patients | Tumor stage | References |
|---|---|---|---|---|---|---|---|
| Colorectal | n.a. | H&E | H&E | Positive | 843 | I–IV | (34) |
| T cells, B cells, FDCs | Gene signature | MA-GES | Positive | 21 | 0–IV | (31) | |
| T cells, B cells, HEV, FDCs, DC-LAMP+DCs |
CD3+ T cells | IHC | Positive | 351 | II–III | (35) | |
| T cells, B cells, CD68+macrophages, CD83+DCs |
CD3+ CD20+ CD68+ CD83+ | IHC | Positive | 884 | I–IV | (27) | |
| T cells, CD83+ DCs | CD3+ T cells, CD83+ DCs | IHC | Positive | 40 | I–IV | (36) | |
| CD8+ T cell, DC-LAMP+DCs | DC-Lamp+ mature DC | IHC | Positive | 25 | ND | (37) | |
| Lung | T cells, B cells, DC-LAMP+DCs, FDCs | DC-LAMP+ mature DC | IHC | Positive | 74 | I–II | (38) |
| T cells, B cells, DC-LAMP+ DCs, HEV | DC-LAMP+ mature DC, | IHC | Positive | 362 | I–IV | (39) | |
| T cells, B cells, DC-LAMP+ DCs, HEV, GCs |
DC-LAMP+, CD20+ B cells | IHC | Positive | 196 | I–III | (40) | |
| Breast | Tregs, T cells, DC-Lamp+ DCs | FoxP3+ | IHC | Negative | 191 | I–III | (41) |
| T cells, B cells | CD3+ T cells, CD20+ B cells | H&E, IHC | Positive | 248 | ND | (42) | |
| T cells, B cells, DC-LAMP+DCs, HEV | DC-LAMP+ DCs | IHC | Positive | 146 | I–III | (43) | |
| T cells, B cells | PNAD+ HEV | IHC | Positive | 146 | I–III | (20) | |
| Melanoma | DC-LAMP+ DCs | DC-LAMP+ | IHC | Positive | 82 | IA–IIIA | (44) |
| DC-LAMP+ DCs | Gene signature | MA-GES | Positive | 21 | IV | (21) |
IHC, immunohistochemistry; Tfh, T helper follicular cells; GC, germinal center; FDCs, follicular dendritic cells; H&E, hematoxilin and eosin staining; DCs, dendritic cells; HEV, high endothelial venules; GES, gene expression signature; MA, microarray.